190 related articles for article (PubMed ID: 11929795)
21. Iron chelators for thalassaemia.
Hershko C; Konijn AM; Link G
Br J Haematol; 1998 Jun; 101(3):399-406. PubMed ID: 9633877
[No Abstract] [Full Text] [Related]
22. Iron chelation therapy.
Hershko CM; Link GM; Konijn AM; Cabantchik ZI
Curr Hematol Rep; 2005 Mar; 4(2):110-6. PubMed ID: 15720959
[TBL] [Abstract][Full Text] [Related]
23. Improvement of iron removal from the reticuloendothelial system by liposome encapsulation of N,N'-bis[2-hydroxybenzyl]-ethylenediamine-N,N'-diacetic acid (HBED). Comparison with desferrioxamine.
Lau EH; Cerny EA; Wright BJ; Rahman YE
J Lab Clin Med; 1983 May; 101(5):806-16. PubMed ID: 6403640
[TBL] [Abstract][Full Text] [Related]
24. Myocyte damage and loss of myofibers is the potential mechanism of iron overload toxicity in congestive cardiac failure in thalassemia. Complete reversal of the cardiomyopathy and normalization of iron load by deferiprone.
Kolnagou A; Michaelides Y; Kontos C; Kyriacou K; Kontoghiorghes GJ
Hemoglobin; 2008; 32(1-2):17-28. PubMed ID: 18274979
[TBL] [Abstract][Full Text] [Related]
25. Deferoxamine Alleviates Iron Overload and Brain Injury in a Rat Model of Brainstem Hemorrhage.
Guo X; Qi X; Li H; Duan Z; Wei Y; Zhang F; Tian M; Ma L; You C
World Neurosurg; 2019 Aug; 128():e895-e904. PubMed ID: 31082547
[TBL] [Abstract][Full Text] [Related]
26. Long-term experience with deferasirox (ICL670), a once-daily oral iron chelator, in the treatment of transfusional iron overload.
Cappellini MD; Taher A
Expert Opin Pharmacother; 2008 Sep; 9(13):2391-402. PubMed ID: 18710363
[TBL] [Abstract][Full Text] [Related]
27. Evaluation of the desferrithiocin pharmacophore as a vector for hydroxamates.
Bergeron RJ; McManis JS; Bussenius J; Brittenham GM; Wiegand J
J Med Chem; 1999 Jul; 42(15):2881-6. PubMed ID: 10425097
[TBL] [Abstract][Full Text] [Related]
28. Exploring the "iron shuttle" hypothesis in chelation therapy: effects of combined deferoxamine and deferiprone treatment in hypertransfused rats with labeled iron stores and in iron-loaded rat heart cells in culture.
Link G; Konijn AM; Breuer W; Cabantchik ZI; Hershko C
J Lab Clin Med; 2001 Aug; 138(2):130-8. PubMed ID: 11477380
[TBL] [Abstract][Full Text] [Related]
29. Acute iron poisoning. Rescue with macromolecular chelators.
Mahoney JR; Hallaway PE; Hedlund BE; Eaton JW
J Clin Invest; 1989 Oct; 84(4):1362-6. PubMed ID: 2794068
[TBL] [Abstract][Full Text] [Related]
30. Combined therapy with desferrioxamine and deferiprone in beta thalassemia major patients with transfusional iron overload.
Daar S; Pathare AV
Ann Hematol; 2006 May; 85(5):315-9. PubMed ID: 16450126
[TBL] [Abstract][Full Text] [Related]
31. Comparison between deferoxamine and deferiprone (L1) in iron-loaded thalassemia patients.
Taher A; Sheikh-Taha M; Koussa S; Inati A; Neeman R; Mourad F
Eur J Haematol; 2001 Jul; 67(1):30-4. PubMed ID: 11553264
[TBL] [Abstract][Full Text] [Related]
32. Benefits and risks of deferiprone in iron overload in Thalassaemia and other conditions: comparison of epidemiological and therapeutic aspects with deferoxamine.
Kontoghiorghes GJ; Neocleous K; Kolnagou A
Drug Saf; 2003; 26(8):553-84. PubMed ID: 12825969
[TBL] [Abstract][Full Text] [Related]
33. Iron chelation in thalassemia: combined or monotherapy? The Egyptian experience.
El-Beshlawy A; Manz C; Naja M; Eltagui M; Tarabishi C; Youssry I; Sobh H; Hamdy M; Sharaf I; Mostafa A; Shaker O; Hoffbrand AV; Taher A
Ann Hematol; 2008 Jul; 87(7):545-50. PubMed ID: 18351337
[TBL] [Abstract][Full Text] [Related]
34. Therapeutic efficacy of different iron chelators in Egyptian children with Beta Thalassemia with iron overload.
Hagag AA; Hamam MA; Taha OA; Hazaa SM
Infect Disord Drug Targets; 2015; 15(2):98-105. PubMed ID: 26205801
[TBL] [Abstract][Full Text] [Related]
35. A randomised comparison of deferasirox versus deferoxamine for the treatment of transfusional iron overload in sickle cell disease.
Vichinsky E; Onyekwere O; Porter J; Swerdlow P; Eckman J; Lane P; Files B; Hassell K; Kelly P; Wilson F; Bernaudin F; Forni GL; Okpala I; Ressayre-Djaffer C; Alberti D; Holland J; Marks P; Fung E; Fischer R; Mueller BU; Coates T;
Br J Haematol; 2007 Feb; 136(3):501-8. PubMed ID: 17233848
[TBL] [Abstract][Full Text] [Related]
36. Iron chelation: new therapies.
Galanello R
Semin Hematol; 2001 Jan; 38(1 Suppl 1):73-6. PubMed ID: 11206965
[TBL] [Abstract][Full Text] [Related]
37. ROS-triggered degradable iron-chelating nanogels: Safely improving iron elimination in vivo.
Liu Z; Qiao J; Nagy T; Xiong MP
J Control Release; 2018 Aug; 283():84-93. PubMed ID: 29792889
[TBL] [Abstract][Full Text] [Related]
38. Nanogel-DFO conjugates as a model to investigate pharmacokinetics, biodistribution, and iron chelation in vivo.
Wang Y; Liu Z; Lin TM; Chanana S; Xiong MP
Int J Pharm; 2018 Mar; 538(1-2):79-86. PubMed ID: 29341909
[TBL] [Abstract][Full Text] [Related]
39. Combination of deferasirox and deferoxamine in clinical practice: an alternative scheme of chelation in thalassemia major patients.
Cassinerio E; Orofino N; Roghi A; Duca L; Poggiali E; Fraquelli M; Zanaboni L; Cappellini MD
Blood Cells Mol Dis; 2014 Sep; 53(3):164-7. PubMed ID: 24846580
[TBL] [Abstract][Full Text] [Related]
40. Combination therapy of deferasirox and deferoxamine shows significant improvements in markers of iron overload in a patient with β-thalassemia major and severe iron burden.
Voskaridou E; Komninaka V; Karavas A; Terpos E; Akianidis V; Christoulas D
Transfusion; 2014 Mar; 54(3):646-9. PubMed ID: 23834310
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
